ACE-CF
Research type
Research Study
Full title
Artificial intelligence to control acute pulmonary exacerbations in cystic fibrosis
IRAS ID
316930
Contact name
Andres Floto
Contact email
Sponsor organisation
Royal Papworth NHS Foundation Trust
ISRCTN Number
ISRCTN27664426
Duration of Study in the UK
2 years, 11 months, 30 days
Research summary
Cystic Fibrosis (CF) is a life limiting, inherited condition that causes a build up of thick, sticky mucus in the lungs and other organs that leads to severe and persistent bacterial infections. CF is characterised by periods of relative stability punctuated abrupt clinical deterioration known as acute pulmonary exacerbations (APEs.) APEs drive pulmonary inflammation, progressive lung damage and premature death. In preliminary studies we have shown that home monitoring empowers patients and can safely reduce routine outpatient hospital attendance by 50%.
Breathe RM Signal is a smartphone app. It uses Bluetooth data from participants monitoring themselves at home with devices such a spirometer, heart rate monitor and weighing scales to see if they are stable or at risk of having an APE. After using their home monitoring equipment participants are able to see an easy-to-understand colour on the app with instructions of what they need to do. The app helps to detect the onset of an APE earlier than symptoms appear, which enables the infection to be treated earlier. This may reduce how much treatment is needed and how long it is needed for. Participants will also be asked to complete quality of life questionnaires during the study. The purpose of this study is to establish if Breathe RM Signal (developed from previous studies where participants monitored physiological parameters at home) improves quality of life, reliably predicts the onset of APEs and is safe to use in clinical practice.REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
23/EE/0031
Date of REC Opinion
13 Mar 2023
REC opinion
Further Information Favourable Opinion